Many thanks Dolcevita - and agreed, hence why:
1. I noted that MSB had many irons in the fire, and that the post was expressly limited to considering the upcoming ODAC review meeting; and
2. Emphasised that MSB has made a biologic licence application, and referred to the data specifically related to the same (rather than simply an application related to “oncologic drugs”). The fact the remains that ODAC is the committee reviewing the application and it reviews applications across the broad spectrum of oncologic products.
banter and General Discussion, page-544
-
- There are more pages in this discussion • 9,619 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.005(0.43%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $2.165M | 1.849M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 44319 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 14760 | 9 |
View Market Depth
| Last trade - 12.53pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |